Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Gimv invests in UK based Prosonix, a specialty pharma company developing novel respiratory medicines


22-5-2012

Gimv, together with a syndicate of life science investors including Ventech, Gilde Healthcare Partners, Entrepreneurs Fund, Quest for Growth and Solon Ventures, invests GBP 5.7 million in the second closing of a Series B equity financing round, totaling GBP 17.1 million, of Prosonix (Oxford, UK). It is a specialty pharmaceutical company developing a portfolio of inhaled respiratory medicines of known and approved drugs, using its own particle engineering technology. The proceeds of the financing will be used to progress the company’s emerging proprietary product pipeline of excipient-free, drug-only inhalable mono- and combination therapies.

Prosonix' (www.prosonix.co.uk) drug development is based on a novel ultrasonic particle engineering approach. Its proprietary technology enables Prosonix to develop ‘smart’ excipient-free, drug-only inhalable particles that are specifically designed to optimally target the site of action in the lung, precisely and consistently, delivering maximum clinical effect. Prosonix’ lead products include a generic drug for asthma (PSX1001) and for chronic obstructive pulmonary disease (PSX1002). The company is also advancing the development of its next-generation combination respiratory medicines. In addition to its internal respiratory pipeline, Prosonix worked on numerous co-development partnerships with leading pharmaceutical companies.

David Hipkiss, Prosonix’ CEO, said: “These new funds will enable Prosonix to accelerate its activities aimed at attaining key performance and clinical data for our pipeline of excipient-free, drug-only respiratory medicines. The potential of our novel particle engineering approach to deliver significant added value and benefits to patients and payors alike has been fundamental in attracting leading investors to back the company.”

Karl Nägler, Venture Capital Partner at Gimv, commented on this transaction: “Prosonix is at an important point in its development. Based on the demonstrated performance of its particle engineering platform and approach, the near-term product opportunities in its pipeline, its highly experienced team and a strong and experienced group of investors, we are confident that Prosonix can become a significant player in the area of respiratory medicines. As such, I am looking forward actively supporting the company to achieve this potential.”

Jim Phillips, Prosonix’ Non-executive Chairman, said: “We welcome Gimv and Karl Nägler to Prosonix, strengthening the investor base, and providing further validation of Prosonix’s progress as a respiratory disease focused company.”

All parties involved decided not to disclose any further financial information regarding this transaction.


Publisher Contact Information:

GIMV N.V.
-
-

Company profile of GIMV N.V.
Past press releases of GIMV N.V. .

Data


25,894
Tech investments
From our Online Data Service
16,759
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Jun 29€1.3MSecurity
Jun 28€2.2MDatabase
Jun 28€12.0MMaterials
Jun 28€5.5MBusiness applications
Jun 27€3.0MBiopharmaceuticals
Jun 27€10.0MEnergy related
Jun 27N/AWireless applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.